UNSPSC 51434939: Hydrochlorothiazide/labetalol

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV400. This VA Drug Class (CV400) classifies this compound as belonging to the group ANTIHYPERTENSIVE COMBINATIONS.

UNSPSC 51434939 Hydrochlorothiazide/labetalol, a Commodity code, identifies a single pharmaceutical product line — specifically combination antihypertensive medications containing hydrochlorothiazide and labetalol — that state and local governments procure for emergency medical services, public health programs, and healthcare benefit systems. Recent solicitations show state and local buyers purchasing individual drug formulations (labetalol HCI vials, adenosine vials, epinephrine injections, and other advanced life support medications) through sealed-bid and cooperative purchasing vehicles. Issuing bodies include municipal fire and rescue departments (Tampa Fire Rescue), state health and human services agencies (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP) that aggregate demand across participating state and local government facilities. Scope encompasses both direct procurement of specific medication line items with firm expiration-date and shelf-life requirements and broader pharmaceutical supply agreements where manufacturers supply products through authorized wholesale distributors under negotiated pricing models.

Geographic activity spans Texas, Florida, Minnesota, and Oregon based on recent solicitations. The City of Tampa's Purchasing Department issued an IFB (Bid No. 26-P-00188) for Advanced Life Support Medications due April 8, 2026, with an estimated contract value of $40,000, requiring vendors to supply 370 units of labetalol HCI 100mg vials and three other cardiac medications for Tampa Fire Rescue, with a one-year term and two optional one-year renewals; the solicitation includes a 5 percent bid discount for Small Local Business Enterprise participation and mandates OSHA-compliant Safety Data Sheets for all medications supplied. The Minnesota Department of Administration's Office of State Procurement, administering MMCAP, issued an RFP (S1070000015802) due March 26, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed to participating state and local facilities in Minnesota and Oregon, with pricing weighted at 75 percent and contract term of two years for new vendors; award was contingent on vendor compliance with cGMP, the Drug Supply Chain Security Act, and maintenance of relationships with at least two of three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, Morris & Dickson). The Texas HHS Commission issued a Request for Information (RFI No. HHS0017013, due April 3, 2026) exploring direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization arrangements, signaling intent to pursue alternative contracting models for pharmaceutical supply.